Medical Device Industry Challenges India's Proposed Regulatory Bill

India's medical device industry has voiced strong opposition to the proposed Drugs, Medical Devices and Cosmetics Bill, 2026, which aims to overhaul the country's regulatory framework. Industry leaders warn that the draft bill, which treats medical devices similarly to pharmaceuticals, poses significant threats to manufacturing, investment, and innovation.

Concerns Over Regulatory Approach

Industry representatives, patient safety groups, and healthcare providers have collectively expressed their dissatisfaction with the bill. They argue that the legislation fails to recognize the fundamental differences between medical devices and pharmaceutical products. A letter addressed to the Union Health Minister highlights concerns that the bill's approach could discourage investment and hinder India's goal of becoming a global hub for medical device manufacturing.

One major point of contention is the bill's use of drug-centric terminology, such as 'adulterated' and 'spurious,' which the industry contends is unsuitable for the regulation of engineering-based medical devices. The letter emphasizes that medical devices should be regulated through risk-based assessments, quality management systems, and post-market surveillance rather than punitive measures typical of pharmaceutical regulation.

Potential Impact on Innovation and Investment

The draft bill proposes severe penalties, including imprisonment for regulatory lapses such as labeling errors and documentation issues, even when no harm results. Industry stakeholders have criticized this approach, noting that regulatory frameworks in regions like the European Union, the United States, Japan, the United Kingdom, and Australia focus on administrative enforcement rather than criminal penalties.

The medical device sector argues that such stringent regulations could stifle innovation and deter foreign investment. The industry is urging the government to adopt a more nuanced approach that reflects the unique nature of medical devices and aligns with international standards.

Call for Re-evaluation

The draft bill is currently under inter-ministerial consultation, and the medical device industry is advocating for a re-evaluation of its provisions. Stakeholders are calling for a regulatory framework that supports growth and innovation while ensuring patient safety. They stress the importance of distinguishing between pharmaceuticals and medical devices in regulatory language and enforcement strategies.

As the debate continues, the industry remains hopeful that the government will consider their concerns and adjust the bill to better support India's burgeoning medical device sector.